Clin2
NCT07550374Possibly a fitNot yet recruiting

New cell injection for advanced Parkinson's after brain surgery

Parkinson's Disease (PD)

Part of Brain & nervous system clinical trials.

This early-stage trial tests NouvNeu001, a new cell-based treatment injected into the brain for people with moderate-to-advanced Parkinson's disease who have already had deep brain stimulation or brain surgery. The goal is to see if it can reduce Parkinson's symptoms when standard treatments are no longer working well.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
10 people
Ages
18 years to 70 years
Study type
Interventional

Who can take part

  • You must be 18–70 years old and have been diagnosed with primary Parkinson's disease (meeting international diagnostic standards)
  • You must have already undergone deep brain stimulation (DBS) or deep brain nucleus lesioning surgery in the past
  • Your Parkinson's symptoms must still be moderately to significantly limiting even with DBS turned on, and you must experience at least 2 hours per day when medications wear off
  • You must be able to safely undergo brain surgery under anesthesia and have MRI/CT scans
  • Your Parkinson's medications must be at a stable dose for at least 4 weeks before starting the trial
  • You must have normal or near-normal blood counts, liver function, and kidney function at screening

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07533591Not yet recruiting· Early Phase 1
Gene therapy for advanced Parkinson's disease using brain surgery

This early-stage trial tests a new gene therapy delivered directly into a specific brain region (the subthalamic nucleus) using stereotactic surgery. It's designed for people with advanced Parkinson's disease who no longer respond well to standard medications or have severe side effects.

Zhejiang, Province
NCT06944522Recruiting· Phase 3
Cell therapy for Parkinson's symptoms

This study tests a new cell therapy called bemdaneprocel to see if it can reduce Parkinson's symptoms and “off” time. The treatment involves transplanting special cells into the brain to help replace lost dopamine-producing cells.

Scottsdale, Arizona
NCT06167681Recruiting· Phase 1/Phase 2
Cell Therapy NouvNeu001 for Parkinson's Disease

This trial tests a new cell therapy called NouvNeu001 for Parkinson's disease. It involves a one-time brain surgery to deliver the treatment, and researchers will check if it's safe and helps with symptoms.

Beijing, Beijing Municipality
NCT07028632Not yet recruiting· Phase 2
Cell therapy for Parkinson's disease: NouvNeu001 trial

This trial tests a new cell therapy, NouvNeu001, for people with Parkinson's disease who have had symptoms for at least 4 years and are having trouble with their current medications. The goal is to see if this treatment is safe and can improve motor symptoms that are not well controlled.

Beijing, Beijing Municipality
NCT06608355Recruiting· Phase 1
Stem cell treatment for early-onset Parkinson's

This trial tests a new stem cell treatment called NouvNeu001 for people with early-onset Parkinson's disease. The goal is to see if it's safe and if it can help improve movement and daily life.

Wuhan, Hubei
NCT07212088Not yet recruiting· Phase 1
Brain cell injection for Parkinson's disease

This trial tests whether injecting special cells into the brain can improve Parkinson's symptoms. It is for people who have had Parkinson's for at least 5 years, take levodopa but still have times when the medication wears off or causes uncontrolled movements.

Hangzhou, Zhejiang

Hear when a new Parkinson's Disease (PD) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.